Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven metastatic, locally recurrent, or
unresectable squamous cell carcinoma or adenocarcinoma of the esophagus The bulk of the
tumor must involve the esophagus or gastroesophageal (GE) junction (for tumors extending
between the GE junction into the proximal stomach) Gastric cancers with only minor GE
junction or distal esophagus involvement are not eligible Measurable or evaluable disease
No prior treatment for metastatic disease No brain metastases No osseous metastases as
only site of disease

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
least 3 months Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count
at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 mg/dL AST or ALT no greater than
2 times upper limit of normal (ULN) Renal: Creatinine no greater than 2 times ULN Calcium
no greater than 12 mg/dL Cardiovascular: No New York Heart Association class III/IV heart
disease No myocardial infarction within 6 months of study No congestive heart failure No
unstable angina No clinically significant pericardial effusion or arrhythmia Neurologic:
No concurrent peripheral neuropathy greater than grade 1 Other: Not pregnant or nursing
Negative pregnancy test Fertile patients must use effective contraception No active
serious infection or medical illness No history of hypersensitivity to drugs containing
Cremophor (teniposide, cyclosporine, or vitamin K) No invasive malignancies within 5
years, except: Curatively treated basal or squamous cell carcinoma of the skin Curatively
treated carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy within 4 weeks of study
No concurrent immunotherapy Chemotherapy: No more than 1 prior chemotherapy regimen or
chemotherapy/radiation therapy given in a neoadjuvant or adjuvant setting No prior
chemotherapy within 4 weeks of study No concurrent chemotherapy Endocrine therapy: No
prior hormonal therapy within 4 weeks of study Concurrent megestrol (Megace) allowed No
other concurrent hormonal therapy Radiotherapy: No prior radiotherapy within 4 weeks of
study No prior radiation to greater than 30% of bone marrow No more than 1 prior
chemotherapy/radiation therapy regimen given in a neoadjuvant or adjuvant setting No
concurrent radiotherapy Surgery: No prior surgery within 2 weeks of study Other: No prior
parenteral antibiotics within 1 week of study